Our broad portfolio is the foundation from which we make healthy possible. In the US, our generics portfolio of approximately 200 generic product families* provides patients with more affordable access to quality medicines. Our growing Specialty Pharma business delivers products that meet important medical needs in central nervous system disorders, parasitic infections and other therapeutic categories. We are also excited about our work to bring patients more affordable biologic therapy options through our biosimilars program, which today includes one filed product and one near-term filing opportunity.
Learn more about our product portfolios:
*As of May 2019